# Oaktree Acquisition Corp. II (OACB)

Source: https://www.quantisnow.com/company/OACB
Generated: 2026-11-15T18:00:21.475Z

- Ticker: OACB
- Exchange: NYSE
- Sector: Finance
- Industry: Business Services
- IPO year: 2020
- Website: oaktreeacquisitioncorp.com/oac-ii

## About

Oaktree Acquisition Corp. II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the industrial and consumer sectors. The company was incorporated in 2020 and is headquartered in Los Angeles, California.

## Latest OACB news and filings

- 2024-11-15 13:00 UTC [Leadership Update] [Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors](https://www.quantisnow.com/insight/certain-closed-end-funds-advised-by-franklin-templeton-fund-adviser-llc-5778147)
- 2022-06-15 15:35 UTC [SEC Form 25 filed by Oaktree Acquisition Corp. II](https://www.quantisnow.com/insight/sec-form-25-filed-by-oaktree-acquisition-corp-ii-3032502)
- 2022-06-09 17:26 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Thursday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-thursday-3010812)
- 2022-06-07 21:23 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-entry-into-3001343)
- 2022-06-07 20:00 UTC [Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination](https://www.quantisnow.com/insight/alvotech-and-oaktree-acquisition-corp-ii-announce-shareholder-approval-of-3000352)
- 2022-06-03 21:28 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-notice-of-2988532)
- 2022-06-03 21:17 UTC [Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-announces-delisting-of-its-securities-effective-2988401)
- 2022-06-02 17:27 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Thursday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-thursday-2980620)
- 2022-05-31 21:19 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-other-events-2968884)
- 2022-05-24 11:10 UTC [Market Insight] [Oaktree Acquisition Corp. II Combination Partner Alvotech Highlights AVT04 Clinical Study](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-combination-partner-alvotech-highlights-avt04-clinical-2932659)
- 2022-05-24 11:00 UTC [Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®](https://www.quantisnow.com/insight/alvotech-clinical-study-results-demonstrate-therapeutic-equivalence-between-biosimilar-candidate-2932591)
- 2022-05-17 12:57 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-regulation-fd-2900995)
- 2022-05-16 19:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Oaktree Acquisition Corp. II](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-oaktree-acquisition-corp-ii-2894772)
- 2022-05-16 12:00 UTC [Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®](https://www.quantisnow.com/insight/alvotech-announces-positive-results-from-a-pharmacokinetic-similarity-study-for-2890340)
- 2022-05-11 12:18 UTC [Market Chatter] [Alvotech Holdings, Oaktree Acquisition Corp. II Set Date For Extraordinary General Meeting Of Shareholders To Approve SPAC Deal As Jun. 7, 2022](https://www.quantisnow.com/insight/alvotech-holdings-oaktree-acquisition-corp-ii-set-date-for-extraordinary-2866439)
- 2022-05-11 12:00 UTC [Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination](https://www.quantisnow.com/insight/alvotech-global-biotech-company-and-oaktree-acquisition-corp-ii-announce-2866225)
- 2022-05-10 21:29 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Oaktree Acquisition Corp. II](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-oaktree-acquisition-corp-ii-2864059)
- 2022-04-22 20:30 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-entry-into-2757732)
- 2022-04-19 22:00 UTC [Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange](https://www.quantisnow.com/insight/alvotech-improves-access-to-capital-and-streamlines-path-to-expected-2739123)
- 2022-04-18 21:11 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-leadership-update-2732182)
- 2022-04-06 11:50 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-regulation-fd-2684999)
- 2022-04-06 11:08 UTC [Market Insight] [Alvotech Holdings S.A. Announces Resolution Of Europe Patent Dispute With AbbVie](https://www.quantisnow.com/insight/alvotech-holdings-sa-announces-resolution-of-europe-patent-dispute-with-2684759)
- 2022-04-06 11:00 UTC [Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie](https://www.quantisnow.com/insight/alvotech-and-stada-pave-way-to-launching-hukyndraavt02-a-citrate-free-2684656)
- 2022-03-30 21:00 UTC [SEC Form 10-K] [SEC Form 10-K filed by Oaktree Acquisition Corp. II](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-oaktree-acquisition-corp-ii-2651028)
- 2022-03-23 20:59 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-regulation-fd-2616981)
- 2022-03-21 14:09 UTC [Market Insight] [Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022](https://www.quantisnow.com/insight/benzingas-top-ratings-upgrades-downgrades-for-march-21-2022-2601246)
- 2022-03-21 13:28 UTC [Market Chatter] [Northland Capital Markets Initiates Coverage On Oaktree Acquisition with Outperform Rating, Announces Price Target of $15](https://www.quantisnow.com/insight/northland-capital-markets-initiates-coverage-on-oaktree-acquisition-with-outperform-2600971)
- 2022-03-21 12:52 UTC [Analyst Coverage Initiated] [Northland Capital initiated coverage on Oaktree Acquisition Corp. II with a new price target](https://www.quantisnow.com/insight/northland-capital-initiated-coverage-on-oaktree-acquisition-corp-ii-with-2600567)
- 2022-03-09 13:25 UTC [Market Insight] [AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar](https://www.quantisnow.com/insight/abbvie-alvotech-resolve-us-patent-dispute-related-to-humira-biosimilar-2545748)
- 2022-03-08 22:26 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-regulation-fd-2543193)
- 2022-03-08 22:06 UTC [Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech's Proposed High-Concentration Biosimilar (AVT02) for Humira®](https://www.quantisnow.com/insight/alvotech-resolves-us-patent-and-trade-secret-disputes-with-abbvie-2542909)
- 2022-02-28 12:12 UTC [Market Chatter] [Oaktree Acquisition's Merging partner Alvotech Announces FDA Accepts Its BLA Supporting Interchangeability For ATV02, A High Concentration, Citrate-Free Biosimilar Candidate For Humira](https://www.quantisnow.com/insight/oaktree-acquisitions-merging-partner-alvotech-announces-fda-accepts-its-bla-2483700)
- 2022-02-28 12:01 UTC [FDA Accepts Alvotech's BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®](https://www.quantisnow.com/insight/fda-accepts-alvotechs-bla-supporting-interchangeability-for-atv02-a-high-2483613)
- 2022-02-23 23:01 UTC [Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan](https://www.quantisnow.com/insight/alvotech-and-fuji-pharma-expand-partnership-for-additional-biosimilar-candidate-2464035)
- 2022-02-16 21:13 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Oaktree Acquisition Corp. II](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-oaktree-acquisition-corp-ii-2429413)
- 2022-02-07 21:43 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Oaktree Acquisition Corp. II (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-oaktree-acquisition-corp-ii-2366384)
- 2022-02-02 12:37 UTC [Market Chatter] [Oaktree Acquisition's Merging Partner, Alvotech Holdings, Announces Co. Enters Exclusive Global Licensing Agreement With BiosanaPharma For Co-Development Of A Proposed Biosimilar To Xolair](https://www.quantisnow.com/insight/oaktree-acquisitions-merging-partner-alvotech-holdings-announces-co-enters-exclusive-2339587)
- 2022-02-02 12:30 UTC [Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)](https://www.quantisnow.com/insight/alvotech-enters-exclusive-global-licensing-agreement-with-biosanapharma-for-co-development-2339505)
- 2022-01-18 22:23 UTC [SEC Form 8-K] [Oaktree Acquisition Corp. II filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-filed-sec-form-8-k-entry-into-2267777)
- 2022-01-18 21:05 UTC [Market Chatter] [Oaktree Acquisition Corp. II SPAC Merger Partner Alvotech Highlights Upsizing Of Oversubscribed PIPE Transaction To ~$175M](https://www.quantisnow.com/insight/oaktree-acquisition-corp-ii-spac-merger-partner-alvotech-highlights-upsizing-2266785)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/OACB
- Earnings history: https://www.quantisnow.com/earnings/OACB
- Dividend history: https://www.quantisnow.com/dividends/OACB
- Insider transactions: https://www.quantisnow.com/insiders/OACB
- Options chain: https://www.quantisnow.com/options/OACB
- SEC 8-K filings only: https://www.quantisnow.com/company/OACB/8-k
- RSS and alerts for OACB: https://www.quantisnow.com/docs/rss-feeds.md